Entering the 21st Century, we have seen tremendous numbers of achievements made by scientists, from Imatinib, the first targeted therapy in oncology therapeutic area, to immune checkpoint inhibitors, a kind of broad-spectrum anticancer drugs based on unique mechanism of immunology. At the same time, along with the development of genetic sequencing technology, scientists are making great difference in the fast-growing field of oncology.

This special Issue looks for brief, straightforward articles describing the current state of precision medicine, outlining major developments that have been achieved or need to occur to move the oncology forward. We also hope authors can identify the potential challenges in oncology therapeutic areas and provide insights to address those challenges.

The goal of this special Issue is to shed light on the progress made in the past decade in precision medicine of oncology, and on its future challenges to provide a thorough overview of this field. This special Issue will inspire, and provide guidance to researchers in oncology therapeutic areas.

(1) the design of response prediction model to immune checkpoint inhibitors therapy based on multidisciplinary methods such as big data and next generation sequencing

(2) Clinical trials and clinical case reports of targeted therapy or immunotherapy

(3) New molecular targets in solid tumor microenvironments

(4) Efficacy evaluation of multi-immunotherapy or targeted therapy in solid tumor

(5) Novel cancer treatment insights mining from big data by interdisciplinary strategies

(6) Management of Immune-Related Adverse Events (irAEs)

(7) Systematic Review on efficacy and safety of new targeted therapies in cancer treatment